
    
      This is a post-marketing long-term specified drug use-result survey study required for
      products in Japan. In the survey, patient registration and data collection will be conducted
      using post-marketing survey data collection system, PostMaNet via the Internet.

      Patients who are eligible for the survey will be registered within 14 days after the start of
      treatment with roxadustat (including the start day of treatment). For all registered patients
      (including discontinuations/dropouts), the investigator will enter the necessary information
      in the case report form (CRF) and send it immediately after the end of the specified
      observation period for each patient.
    
  